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Background/aim: Postnatal corticosteroids are commonly used to treat bronchopulmonary dysplasia (BPD). We aimed to show
whether S100 calcium-binding B (S100B), neuron-specific enolase (NSE), Tau protein or microtubule-associated protein tau (MAPT),
and glial fibrillary acid protein (GFAP) levels would provide any evidence of early neurological damage in premature infants receiving
postnatal low dose dexamethasone therapy for BPD treatment.
Materials and methods: In this cohort study, 136 preterm infants diagnosed with BPD at ≤32 weeks of gestation formed the study
group, and 64 preterm infants formed the control group. NSE, S100B, GFAP, and MAPT levels were first measured before the postnatal
corticosteroid treatment in both the patient and the control group on the 28th day and, for a second time, after treatment termination
in the patient group.
Results: There were significant differences between the measured GFAP, MAPT, and NSE values of the BPD and control groups on the
28th day, whereas there was no significant difference between the measured S100B values of the two groups. There were a statistically
significant difference between the NSE values measured on the 28th day and after the treatment within the BPD group, whereas no
significant difference existed between the GFAP, MAPT, and S100B values.
Conclusion: NSE levels, which indicate brain damage in the early period, increased in preterm babies with BPD who had been
administered postnatal dexamethasone.
Key words: Bronchopulmonary dysplasia, neuron-specific enolase, microtubule-associated proteins, glial fibrillary acidic protein, S100
proteins

1. Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung
disease that affects more than 40% of preterm newborns
[1]. Postnatal corticosteroids (CS) are generally used
to prevent or treat BPD in preterm infants [2,3].
Dexamethasone is the most commonly used agent for this
purpose [4]. Postnatal CS use, particularly dexamethasone,
has been associated with adverse neurodevelopmental
outcomes, particularly cerebral palsy [5,6,7]. The DART
(dexamethasone: a randomized trial) study showed
that low-dose dexamethasone may provide short term
advantages without significantly increasing the risk of
long-term neurological problems in preterm newborns
[8].
Neurobiomarkers (NBs) seem to provide physicians
with promising helpful data for the early detection of brain

injury in daily clinical practice. Some studies have shown
that multiple biomarkers, rather than a single biomarker,
may provide additional precision in the early evaluation of
cases at risk of neonatal neuronal damage [9]. Therefore,
we studied four NBs indicating brain damage, namely
S100 calcium-binding B (S100B) proteins, neuronspecific enolase (NSE), Tau protein or microtubuleassociated protein tau (MAPT), and glial fibrillary acid
protein (GFAP). Although several studies show long term
neurodevelopmental outcomes of postnatal CS use for the
treatment of preterm infants, no study has yet shown acute
neurological injury occurring during that treatment. In this
study, we aimed to show whether NSE, S100B, MAPT, and
GFAP levels would provide evidence of early neurological
damage in premature infants receiving postnatal low-dose
dexamethasone therapy to treat BPD.
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2. Materials and methods
2.1. Study design
This cohort study was carried out between January
2018 and June 2019 in Dicle University Medical Faculty
Neonatal Intensive Care Unit. The study protocol was
approved by the Dicle University Faculty of Medicine
Ethics Committee (21.12.2017-03), and the study was
conducted in compliance with the universal principles of
the Helsinki Declaration. Written and informed consent
was obtained from the parents of all participants. Clinical
data and blood samples were collected prospectively.
2.2. Study groups
Group 1 (patient group): patients who were born at
≤32 weeks of gestation, diagnosed with BPD, in need
of respiratory support on the postnatal 28th day, and
administered low dose dexamethasone treatment.
Group 2 (control group): patients who were born at
≤32 weeks of gestation, and who received no respiratory
support on the postnatal 28th day.
2.3. Inclusion criteria
1- Preterm babies born at ≤32 (22 0/7-32 6/7)
gestational week.
2- Patient group: On the postnatal 28th day, patients who
needed respiratory support (in the form of conventional
mechanical ventilation, nasal continuous positive airway
pressure, or oxygen therapy in the incubator) but had no
evidence of infection were diagnosed with BPD.
3- Control group: patients who had no need for
respiratory support on the postnatal 28th day.
2.4. Exclusion criteria
1- Having chromosomal disorders (such as trisomy 13,
18, 21),
2- Having major congenital malformations,
3- Receiving corticosteroid therapy for any reason
between birth and the 28th day of life,
4- Having a history of maternal chorioamnionitis,
5- Having patent ductus arteriosus,
6- Having intraventricular bleeding,
7- Having any proven infection.
2.5. Exclusion criteria for discontinuation of
glucocorticoid therapy
1- Suspected infection,
2- Nutritional intolerance,
3- Clinical deterioration,
4- Necrotizing enterocolitis,
5- Gastrointestinal bleeding,
6- Intracranial bleeding,
7- Dexamethasone use for extubation.
2.6. Dexamethasone therapy
In accordance with the DART study protocol [8], patients
with BPD were administered intravenous low-dose
dexamethasone therapy at a cumulative dose of 0.89 mg/
kg for 10 days.
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2.7. Collection of samples
In the patient group participated in the study, the first
venous blood sample was taken immediately before lowdose dexamethasone treatment was administered on the
postnatal 28th day, and then the treatment was started. A
second venous blood sample was taken 12 h after the last
dose of treatment was administered. Control venous blood
sample was taken on the postnatal 28th day in the control
group. Blood samples were taken from the median cubital
vein in the antecubital fossa. Serum samples were then
stored at –80 °C until analysis.
2.8. Laboratory analysis
A commercial enzyme-linked immunosorbent assay
(ELISA) was used to measure NSE, S100B, GFAP, and
MAPT (Shanghai Sunredbio Technology Co., Ltd,
Shanghai, China). Biomarkers were measured in ng/mL
with the ELISA method. The catalog numbers of NSE,
S100B, GFAP, and MAPT ELISA kits used in the study are
210-12-0938, 201-12-4851, 201-12-2095, and 20112-4259,
respectively.
As stated below in the manufacturer’s instructions,
each of the four ELISA kits were studied separately. The
kit uses a double-antibody sandwich ELISA to assay
the level of human kit in samples. The kit is added to
monoclonal antibody enzyme well, which is pre-coated
with human kit monoclonal antibody, incubation, then,
(kit) antibodies labeled with biotin and combined with
Streptavidin-HRP were added to form immune complex.
Then, incubation and washing were carried out again to
remove the uncombined enzyme. Later, when chromogen
solution A, B was added, the color of the liquid changed
into the blue, and, as a result of the effect of the acid, the
color finally becomes yellow. The chroma of color and the
concentration of the human substance kit of sample were
positively correlated.
2.9. Statistical analysis
The Statistical Package for Social Science (version 22;
IBM Corp. Armonk, NY, USA) was used for statistical
analysis. Normality of the distribution of numerical data
was examined using Shapiro–Wilk test. Inter-group
differences were compared using unpaired Student
t-test. Normally distributed numerical variables were
presented as mean (SD). Skewed numerical variables were
presented as median (interquartile range). Inter-group
differences were compared using Mann Whitney–U test.
Ordinal variables were compared using χ2 test for trend;
comparison between two paired non-parametric variables
was performed with Wilcoxon rank test. Correlations
were examined with Pearson product-moment correlation
for parametric numerical variables, and Spearman rank
correlation for non-parametric numerical variables, as
appropriate.
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Receiver-operating characteristic (ROC) curve analysis
was used to examine the value of continuous variables.
To assess the overall accuracy of the ROC analyses, the
area under the curves (AUCs) were measured. Tests with
a p value of less than 0.05 were considered statistically
significant.
3. Results
In this study, the BPD group consisted of 73 (53.7%) boys
and 63 (46.3%) girls, making a total of 136 patients; the
control group consisted of 37 (57.8) boys and 27 (42.2%)
girls, making a total of 64 preterm infants. There was no
statistically significant difference between the groups
regarding sex distribution (p = 0.347). In the BPD group,
88.5% (n = 108) of the patients had a history of antenatal
steroid use, while the corresponding figure in the control
group was 63% (n = 34) (p ≤ 0.001). The mean gestational
age (weeks) was 27.62 ± 2.75 in the BPD group and 28.00 ±
1.45 in the control group; the mean birth weight was 1008
± 307 g in the BPD group and 1068 ± 179 g in the control
group (p = 0.299, p = 0.155, respectively).
In the BPD group, no significant difference was
found between patients with a history antenatal steroid

use and those without with regard to the 28-day GFAP,
MAPT, NSE, and S100B values. In addition, no significant
difference was found between the BPD and control groups
for the same parameters (p = 0.215, p = 0.835, p = 0.618, p
= 0.653, respectively).
There was a significant difference between the BPD
group and the control group with respect to the GFAP,
MAPT, and NSE values measured on the 28th day, whereas
no significant difference was found between the S100B
values of both groups (Table 1). A significant difference
was found between the NSE values but not GFAP, MAPT,
and S100B values measured on the 28th day and after the
treatment in the BPD group (Table 2).
There was a significant correlation between the GFAP,
MAPT, NSE, and S100B values measured on the 28th day
and other parameters in the BPD group (Table 3).
ROC analysis results of GFAP, MAPT, NSE and S100B
values measured on the 28th day in the BPD group are
given in Table 4. See Figure for the ROC curve graph.
4. Discussion
Detection of perinatal brain damage in the acute phase in
term and preterm newborns is still an unsolved problem.

Figure. ROC curve graph of GFAP, MAPT, NSE and S100B values.
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Table 1. Comparison of measured values of GFAP (ng/mL), MAPT (ng/mL), NSE (ng/mL), and
S100B (ng/mL) on 28 days of BPD group, and control group cases.
BPD group (n = 136)

Control group (n = 64)

Parameters*

Mean ± SD

Mean ± SD

p

GFAP

1.530 ± 4.372

0.91 ± 1.019

0.019

MAPT

24.22 ± 31.01

24.56 ± 27.34

0.012

NSE

8.86 ± 14.48

5.19 ± 5.094

0.000

S100B

361.16 ± 396.40

392.12 ± 389.5

0.465

* Parameters measured on the 28th day after birth. BPD: bronchopulmonary dysplasia, SD: standard
deviation.
Table 2. Comparison of GFAP (ng/mL), MAPT (ng/mL), NSE (ng/mL), and S100B (ng/mL) values of BPD group
on 28th day and after treatment.
Negative Ranks

Positive Ranks

Parameters

N (Mean Rank)–(Sum of Ranks)

N (Mean Rank) – (Sum of Ranks)

p*

GFAP

64 (57.63) – (3688)

59 (66.75) – (3938)

0.752

MAPT

136 (55d) – (60,29)

66 (61.59)- (4065)

0.333

NSE

46 (59.11) – (2719)

75 (62.16) – (4662)

0.012

S100B

61 (58.20)v(3550)

62 (65.74)v(4076)

0.507

* Wilcoxon signed ranks test.
Table 3. Correlation between GFAP (ng/mL), MAPT (ng/mL), NSE (ng/mL), and S100B (ng/mL) values and other
parameters of the cases measured on the 28th day.
Parameters

GFAP
r

MAPT
p**

GFAP*

NSE

S100B

r

p**

r

p**

r

p**

0.484

<0.001

0.435

<0.001

0.618

<0.001

0.538

<0.001

0.568

<0.001

0.458

<0.001

MAPT*

0.484

<0.001

NSE*

0.435

<0.001

0.538

<0.001

S100B*

0.618

<0.001

0.568

<0.001

0.458

<0.001

*28 days measured value, **Spearman’s rho.

Currently, studies to find a reliable biomarker that can
predict perinatal brain damage in high-risk newborns
are still ongoing [9]. While severe neurodevelopmental
deficiencies (17% to 59%) occur in short-term follow-up in
premature neonates between 22 and 25 weeks of gestation,
it is generally related with a mortality rate as high as 50%.
Long-term negative consequences include cerebral palsy
(9% to 18%), mental disability (5% to 36%), deafness (2%
to 4%), and blindness (0.7% to 9%) [10].
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NSE is a glycolytic enzyme, which can be detected
in high concentrations in the neuron cell cytoplasm and
is released into the extracellular space in cell death [9].
It is an early biochemical predictor of brain damage in
newborns and can also help us understand the extent
of neuronal damage and assess its prognosis [11]. The
S100B protein is highly specific for the nervous system,
and is secreted in large amounts from astrocytes into the
blood and cerebrospinal fluid (CSF) in neuronal tissue
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Table 4. Sensitivity and specificity at cut-off points of GFAP (ng/mL), MAPT (ng/mL), NSE (ng/mL) and S100B (ng/mL)
values measured on the 28th day for BPD diagnosis.
Indicators

Area under the
ROV curve

(%95 CI)

Cutt-of point
(ng/mL)

p

Sensitivity
(%)

Specifícity
(%)

GFAP

0.600

0.510

0.690

0.588594

0.023

61.5

39.1

MAPT

0.607

NSE

0.680

0.510

0.704

17.28005

0.015

61.5

37.5

0.594

0.766

4.216890

<0.001

65.2

34.4

S100B

0.529

0.430

0.627

234.4936

0.513

50.5

50.0

damage [9]. GFAP is an intermediate filament protein of
the cytoskeleton in astroglia in the nervous system and
is rapidly released into the blood in brain injury [12,13].
MAPT is a microtubule-related structural protein that
is released from neurons into CSF or blood when brain
damage occurs [14].
Antenatal CS has a proven benefit in preventing
complications by ensuring rapid maturation of organs
that do not show the desired development in the fetal
life. Although these drugs have clinically proven positive
effects, they can also trigger some negative developmental
side effects [15]. In our study, no statistically significant
difference was found between patients with and without
a history of antenatal CS use with respect to the brain
damage neurobiomarkers including GFAP, MAPT, NSE,
and S100B measured on the 28th day (p = 0.215, p = 0.835,
p = 0.618, p = 0.653, respectively).
Bronchopulmonary dysplasia is a chronic lung disease
that occurs as a result of barotrauma and oxygen toxicity
caused by mechanical respiratory support in extremely
low birth weight premature neonates. It is a disease with
elevated morbidity and mortality risk. CSs play a major role
in the treatment of BPD resulting from lung inflammation.
CS treatment shows positive effects by rapidly improving
lung function, but studies have shown that this treatment
may also be associated with several serious side effects
in the long term [16]. Systemically administered
dexamethasone is the most commonly used CS to prevent
and treat BPD. It has alarming long term negative effects
associated with its use, the worst of which is cerebral palsy
[17]. Doyle et al. [8] found no strong relationship with its
use and long-term morbidity although the research failed
to provide conclusive evidence about the long term effects
of low dose dexamethasone after the first week of life in
ventilator-dependent neonates. However, Qin G et al. [5]
showed that postnatal dexamethasone use is related with
an elevated risk of neurodevelopmental impairment in
extremely preterm newborns.
A large number of studies have been conducted to
show brain injury in newborn infants, with most being
on hypoxic-ischemic encephalopathy (HIE). It was
reported that the concentrations of GFAP, S-100, and NSE

were significantly elevated in the cerebrospinal fluid of
asphyxiated newborns and significantly associated with
other markers of long term prognosis and brain injury at 1
years of age [17]. Chaparro-Huerta et al. [18] showed that
serum levels of proinflammatory cytokines, S-100B, and
NSE were significantly elevated in newborns with brain
injury compared to controls. In another study, Lu et al. [19]
suggested that in preterm infants, cord blood S100B had
the highest sensitivity for brain injury. Several studies have
shown changes in serum Tau protein levels in brain injury
of the newborn [14]. In our study, a statistically significant
difference was found between the GFAP, MAPT, and NSE
values measured on the 28th day of the BPD group and
the control group, while there was no significant difference
between the S100B values. Summanen et al. [20] showed
that cord blood S100B in term neonates is a weak predictor
of brain injury. In our study, when the correlation between
measured NB values and other parameters was evaluated
on the 28th day of the cases, GFAP, MAPT, NSE and S100B
values showed significant correlations with each other.
Cerebrospinal fluid’sNSE concentrations provide
invaluable information as a clinical reflection of the
severity of hypoxic-ischemic neuronal damage, and this
information may be a harbinger of an abnormal result
at two years of age [21]. In a previous study, NSE levels
were correlated to neonatal HIE grade and an adverse
outcome. The findings suggested that NSE is an accurate
biochemical marker for early prediction of hypoxic
ischemic brain injury in asphyctic newborns [22]. Sun
et al. [23] recently reported that S100B and CSF-NSE
levels were correlated to neurodevelopmental outcomes.
Catherine et al. [24] evaluated whether serum levels of
neuronal biomarkers correlated to neurodevelopmental
outcomes in term neonates at 18 months who hypoxic
ischemic encephalopathy and therapeutic hypothermia.
They showed that serum neuronal biomarkers, S100B,
and NSE levels were not correlated to long-term
neurodevelopmental outcomes in that population. The
predictive ability of serum NSE levels for poor outcomes
appears to be better than predictive ability for moderate or
severe HIE. The sensitivity and specificity values of serum
NSE (cut-off value 40.0 μg/L) as a predictor of moderate
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to severe HIE were 79% and 70%, respectively, and as a
predictor of poor outcomes (cut-off value 45.4 μg/L) it had
a sensitivity of 84% and a specificity of 70% [25].
A systematic review showed that NSE may be a sensitive
and quantitative NB of neuronal damage [13]. In our study,
a significant difference was found between the NSE values
measured on the 28th day and after the treatment in the
BPD group, while there was no significant difference
between the measured GFAP, MAPT, and S100B values. In
our study, sensitivity and specificity values for NSE, GFAP,
and MAPT were 65.2% and 34.4% (cut-off value 4.21 ng/
mL), 61.5% and 39.1% (cut-off value 0.59 ng/mL), and
61.5% and 37.5% (cut-off value 17.28 ng/mL), respectively.
The sensitivity and specificity values of S100B were 50.5%
and 50.0% (cut-off value 234.49 ng/mL), respectively.
No study has yet shown any evidence of neurological
injury in the early period (>28 days) in patients with BPD.
In this study, we found that the BPD group had higher
levels of neuronal injury NBs than the control group. This
finding indicates that respiratory distress experienced by
BPD patients may cause neuronal injury in the early period.
It is also unknown how much exposure to CS given for
treatment contributes to neurological injury early in life. In
our study, we aimed to show whether the lowest cumulative
dose of postnatal dexamethasone exposure contributes to
this brain injury in premature babies diagnosed with BPD.
Statistically, we observed that there was a slight increase in
NSE levels after treatment discontinuation in the patient
group. This finding raises the question that CS can be
associated with brain injury, even at low doses. What will
be the long term clinical consequences of this increase in
premature babies is an issue to be investigated.
This study has some limitations. Firstly, the diagnosis
of BPD is made on the 28th day in premature patients
who need respiratory support. Secondly, the long-term

clinical results of the data obtained in such short term in
this study are unknown. However, our study was aimed at
obtaining evidence of early brain injury, and it has already
planned to follow up these patients and evaluate their
future clinical results in the future. Another issue worth
mentioning which is the NBs used for demonstrating brain
injury, was also studied mostly in CSF in earlier studies but
in blood in our study. The reason is that, in our study, an
invasive attempt was not made to collect CSF samples from
premature newborns due to ethical limitations.
This study showed that the levels of neurobiomarkers
indicating early brain injury are increased in preterm
babies with BPD. Although our study cannot provide
conclusive evidence about the long term effects of low-dose
dexamethasone after the first four weeks of life in premature
neonates with BPD, it still suggests that there may be a
relationship between NSE levels and neurodevelopmental
outcome. However, well-designed studies with a greater
number of patients using multiple neurobiomarkers are
needed.
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